ReviewOncogene2000
Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis.
Review in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 433 citations in OpenAlex.
- Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment.Medicine · 2018Trial
- Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.Cancer science · 2015Trial
- Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.Neuro-oncology · 2012Trial
- Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010Trial
- Article
- Post-marketing signal detection of fruquintinib-associated adverse events using the FAERS database.Medicine · 2026Article
- Artery formation in the intestinal wall and mesentery by intestine-derived Esm1+ endothelial cells.Nature communications · 2025Article
- Dysregulated lymphatic remodeling promotes immunopathology during non-healing cutaneous leishmaniasis.bioRxiv : the preprint server for biology · 2025Article
- Prognostic markers in oesophageal and gastric cancer review. Are they ready for clinical practice?ESMO gastrointestinal oncology · 2024Review
- Investigation of coagulation and proteomics profiles in symptomatic feline hypertrophic cardiomyopathy and healthy control cats.BMC veterinary research · 2024Article
- The tyrosine kinase KDR is essential for the survival of HTLV-1-infected T cells by stabilizing the Tax oncoprotein.Nature communications · 2024Article
- Tissue-resident macrophages specifically express Lactotransferrin and Vegfc during ear pinna regeneration in spiny mice.Developmental cell · 2024Article
- Epsin Endocytic Adaptor Proteins in Angiogenic and Lymphangiogenic Signaling.Cold Spring Harbor perspectives in medicine · 2024Review
- Profile of Fruquintinib in the Management of Advanced Refractory Metastatic Colorectal Cancer: Design, Development and Potential Place in Therapy.Drug design, development and therapy · 2024Review
- Targeted Delivery of Diphtheria Toxin into VEGFR1/VEGFR2 Overexpressing Cells Induces Anti-angiogenesis Activity.Current protein & peptide science · 2024Article
- Vascular endothelial growth factor-C in activating vascular endothelial growth factor receptor-3 and chemokine receptor-4 in melanoma adhesion.Journal of cellular and molecular medicine · 2022Review
- FLT4/VEGFR3 activates AMPK to coordinate glycometabolic reprogramming with autophagy and inflammasome activation for bacterial elimination.Autophagy · 2022Article
- Recent Advances in the Biological Activity of s-Triazine Core Compounds.Pharmaceuticals (Basel, Switzerland) · 2022Review
- 3D Printing of Diatomite Incorporated Composite Scaffolds for Skin Repair of Deep Burn Wounds.International journal of bioprinting · 2022Article
- Review: Neurological Complications From Therapies for Pediatric Brain Tumors.Frontiers in oncology · 2022Review
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
VEGFR-1 (Flt-1), VEGFR-2 (KDR) and VEGFR-3 (Flt4) are endothelial specific receptor tyrosine kinases, regulated by members of the vascular endothelial growth factor family. VEGFRs are indispensable for embryonic vascular development, and are involved in the regulation of many aspects of physiological and pathological angiogenesis. VEGF-C and VEGF-D, as ligands for VEGFR-3 are also capable of stimulating lymphangiogenesis and at least VEGF-C can enhance lymphatic metastasis. Recent studies have shown that missense mutations within the VEGFR-3 tyrosine kinase domain are associated with human hereditary lymphedema, suggesting an important role for this receptor in the development of the lymphatic vasculature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.